Conformational conversion of prion protein in prion diseases

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 6, 2013, Pages 465-476

  Zhou, Zheng ^a   Xiao, Gengfu ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Cofactor; Conformational conversion; Prion disease; Prion protein

Indexed keywords

COFACTOR; PRION PROTEIN;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATIONAL CONVERSION; GENETICS; HUMAN; METABOLISM; MUTATION; PRION; PRION DISEASE; PROTEIN CONFORMATION; PROTEIN PROCESSING; REVIEW;

COFACTOR; CONFORMATIONAL CONVERSION; PRION DISEASE; PRION PROTEIN;

ANIMALS; HUMANS; MODELS, MOLECULAR; MUTATION; PRION DISEASES; PRIONS; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84879239317     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt027     Document Type: Review

References (165)

1. Aguzzi A and Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009, 89: 1105-1152.
2. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216: 136-144.
3. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998, 95: 13363-13383.
4. Cohen FE and Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem 1998, 67: 793-819.
5. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF and Caughey WS. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 1991, 30: 7672-7680.
6. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A and Groth D, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993, 90: 10962-10966.
7. Prusiner SB. Molecular biology of prion diseases. Science 1991, 252: 1515-1522.
8. Aguzzi A and Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004, 116: 313-327.
9. Jarrett JT and Lansbury PT, Jr. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73: 1055-1058.
10. Ferrone F. Analysis of protein aggregation kinetics. Methods Enzymol 1999, 309: 256-274.
11. Baskakov IV. Branched chain mechanism of polymerization and ultrastructure of prion protein amyloid fibrils. Febs J 2007, 274: 3756-3765.
12. Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F and Billeter M, et al. NMR solution structure of the human prion protein. Proc Natl Acad Sci USA 2000, 97: 145-150.
13. Knaus KJ, Morillas M, Swietnicki W, Malone M, Surewicz WK and Yee VC. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat Struct Biol 2001, 8: 770-774.
14. Govaerts C, Wille H, Prusiner SB and Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci USA 2004, 101: 8342-8347.
15. Cobb NJ, Sonnichsen FD, McHaourab H and Surewicz WK. Molecular architecture of human prion protein amyloid: a parallel, in-register betastructure. Proc Natl Acad Sci USA 2007, 104: 18946-18951.
16. Smirnovas V, Baron GS, Offerdahl DK, Raymond GJ, Caughey B and Surewicz WK. Structural organization of brain-derived mammalian prions examined by hydrogen-deuterium exchange. Nat Struct Mol Biol 2011, 18: 504-506.
17. Fasano C, Campana V and Zurzolo C. Prions: protein only or something more? Overview of potential prion cofactors. J Mol Neurosci 2006, 29: 195-214.
18. Gill AC, Agarwal S, Pinheiro TJ and Graham JF. Structural requirements for efficient prion protein conversion: cofactors may promote a conversion-competent structure for PrP(C). Prion 2010, 4: 235-242.
19. Surewicz WK and Apostol MI. Prion protein and its conformational conversion: a structural perspective. Top Curr Chem 2011, 305: 135-167.
20. Ma J. The role of cofactors in prion propagation and infectivity. PLoS Pathog 2012, 8: e1002589.
21. Tanaka M, Chien P, Naber N, Cooke R and Weissman JS. Conformational variations in an infectious protein determine prion strain differences. Nature 2004, 428: 323-328.
22. Tanaka M, Collins SR, Toyama BH and Weissman JS. The physical basis of how prion conformations determine strain phenotypes. Nature 2006, 442: 585-589.
23. Angers RC, Kang HE, Napier D, Browning S, Seward T, Mathiason C and Balachandran A, et al. Prion strain mutation determined by prion protein conformational compatibility and primary structure. Science 2010, 328: 1154-1158.
24. Rossetti G, Cong X, Caliandro R, Legname G and Carloni P. Common structural traits across pathogenic mutants of the human prion protein and their implications for familial prion diseases. J Mol Biol 2011, 411: 700-712.
25. Hosszu LL, Tattum MH, Jones S, Trevitt CR, Wells MA, Waltho JP and Collinge J, et al. The H187R mutation of the human prion protein induces conversion of recombinant prion protein to the PrP(Sc)-like form. Biochemistry 2010, 49: 8729-8738.
26. Ilc G, Giachin G, Jaremko M, Jaremko L, Benetti F, Plavec J and Zhukov I, et al. NMR structure of the human prion protein with the pathological Q212P mutation reveals unique structural features. PLoS one 2010, 5: e11715.
27. Biljan I, Ilc G, Giachin G, Raspadori A, Zhukov I, Plavec J and Legname G. Toward the molecular basis of inherited prion diseases: NMR structure of the human prion protein with V210I mutation. J Mol Biol 2011, 412: 660-673.
28. van der Kamp MW and Daggett V. Pathogenic mutations in the hydrophobic core of the human prion protein can promote structural instability and misfolding. J Mol Biol 2010, 404: 732-748.
29. Apetri AC, Surewicz K and Surewicz WK. The effect of diseaseassociated mutations on the folding pathway of human prion protein. J Biol Chem 2004, 279: 18008-18014.
30. Surewicz WK, Jones EM and Apetri AC. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro. Accounts Chem Res 2006, 39: 654-662.
31. Shen L and Ji HF. Mutation directional selection sheds light on prion pathogenesis. Biochem Biophys Res Commun 2011, 410: 159-163.
32. Zhang Y, Swietnicki W, Zagorski MG, Surewicz WK and Sonnichsen FD. Solution structure of the E200K variant of human prion protein. Implications for the mechanism of pathogenesis in familial prion diseases. J Biol Chem 2000, 275: 33650-33654.
33. Yin S, Yu S, Li C, Wong P, Chang B, Xiao F and Kang SC, et al. Prion proteins with insertion mutations have altered N-terminal conformation and increased ligand binding activity and are more susceptible to oxidative attack. J Biol Chem 2006, 281: 10698-10705.
34. Zanusso G, Petersen RB, Jin T, Jing Y, Kanoush R, Ferrari S and Gambetti P, et al. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem 1999, 274: 23396-23404.
35. Jin T, Gu Y, Zanusso G, Sy M, Kumar A, Cohen M and Gambetti P, et al. The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J Biol Chem 2000, 275: 38699-38704.
36. Ma J and Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci USA 2001, 98: 14955-14960.
37. Ashok A and Hegde RS. Selective processing and metabolism of diseasecausing mutant prion proteins. PLoS Pathog 2009, 5: e1000479.
38. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M and DeArmond SJ, et al. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998, 279: 827-834.
39. Gu Y, Verghese S, Bose S, Mohan M and Singh N. Mutant prion protein D202N associated with familial prion disease is retained in the endoplasmic reticulum and forms 'curly' intracellular aggregates. J Mol Neurosci 2007, 32: 90-96.
40. Martin L, Latypova X and Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 2011, 58: 458-471.
41. Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 2006, 112: 237-251.
42. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL and Prusiner SB. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 1993, 32: 1991-2002.
43. Giannopoulos PN, Robertson C, Jodoin J, Paudel H, Booth SA and LeBlanc AC. Phosphorylation of prion protein at serine 43 induces prion protein conformational change. J Neurosci 2009, 29: 8743-8751.
44. Ikeda S, Kobayashi A and Kitamoto T. Thr but Asn of the N-glycosylation sites of PrP is indispensable for its misfolding. Biochem Biophys Res Commun 2008, 369: 1195-1198.
45. Hornemann S, Schorn C and Wuthrich K. NMR structure of the bovine prion protein isolated from healthy calf brains. EMBO Rep 2004, 5: 1159-1164.
46. Lehmann S and Harris DA. Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells. J Biol Chem 1997, 272: 21479-21487.
47. Korth C, Kaneko K and Prusiner SB. Expression of unglycosylated mutated prion protein facilitates PrP(Sc) formation in neuroblastoma cells infected with different prion strains. J Gen Virol 2000, 81: 2555-2563.
48. Winklhofer KF, Heller U, Reintjes A and Tatzelt J. Inhibition of complex glycosylation increases the formation of PrPSc. Traffic 2003, 4: 313-322.
49. Ermonval M, Mouillet-Richard S, Codogno P, Kellermann O and Botti J. Evolving views in prion glycosylation: functional and pathological implications. Biochimie 2003, 85: 33-45.
50. Lawson VA, Collins SJ, Masters CL and Hill AF. Prion protein glycosylation. J Neurochem 2005, 93: 793-801.
51. Kim JI, Surewicz K, Gambetti P and Surewicz WK. The role of glycophosphatidylinositol anchor in the amplification of the scrapie isoform of prion protein in vitro. FEBS Lett 2009, 583: 3671-3675.
52. Priola SA and Lawson VA. Glycosylation influences cross-species formation of protease-resistant prion protein. EMBO J 2001, 20: 6692-6699.
53. Baron GS, Hughson AG, Raymond GJ, Offerdahl DK, Barton KA, Raymond LD and Dorward DW, et al. Effect of glycans and the glycophosphatidylinositol anchor on strain dependent conformations of scrapie prion protein: improved purifications and infrared spectra. Biochemistry 2011, 50: 4479-4490.
54. Sim VL and Caughey B. Ultrastructures and strain comparison of underglycosylated scrapie prion fibrils. Neurobiol Aging 2009, 30: 2031-2042.
55. Ritchie MA, Hunt LG and Gill AC. Lysine hydroxylation and O-glycosylation in the globular, C-terminal region of mammalian-expressed, recombinant PrP. Int J Mass Spectrom 2012. In Press, Available at: http://www.sciencedirect.com/ science/journal/aip/13873806.
56. Chen PY, Lin CC, Chang YT, Lin SC and Chan SI. One O-linked sugar can affect the coil-to-beta structural transition of the prion peptide. Proc Natl Acad Sci USA 2002, 99: 12633-12638.
57. Wong BS, Brown DR, Pan T, Whiteman M, Liu T, Bu X and Li R, et al. Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J Neurochem 2001, 79: 689-698.
58. Butterfield DA and Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 2001, 122: 945-962.
59. Freixes M, Rodriguez A, Dalfo E and Ferrer I. Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol Aging 2006, 27: 1807-1815.
60. Pamplona R, Naudi A, Gavin R, Pastrana MA, Sajnani G, Ilieva EV and Del Rio JA, et al. Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic Biol Med 2008, 45: 1159-1166.
61. Dear DV, Young DS, Kazlauskaite J, Meersman F, Oxley D, Webster J and Pinheiro TJ, et al. Effects of post-translational modifications on prion protein aggregation and the propagation of scrapie-like characteristics in vitro. Biochim Biophys Acta 2007, 1774: 792-802.
62. Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes ME, Langeveld J and Sklaviadis T, et al. Methionine sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry 2008, 47: 8866-8873.
63. Canello T, Frid K, Gabizon R, Lisa S, Friedler A, Moskovitz J and Gasset M. Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP. PLoS Pathog 2010, 6: e1000977.
64. Redecke L, Binder S, Elmallah MI, Broadbent R, Tilkorn C, Schulz B and May P, et al. UV-light-induced conversion and aggregation of prion proteins. Free Radic Biol Med 2009, 46: 1353-1361.
65. Redecke L, von Bergen M, Clos J, Konarev PV, Svergun DI, Fittschen UE and Broekaert JA, et al. Structural characterization of beta-sheeted oligomers formed on the pathway of oxidative prion protein aggregation in vitro. J Struct Biol 2007, 157: 308-320.
66. Requena JR, Groth D, Legname G, Stadtman ER, Prusiner SB and Levine RL. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proc Natl Acad Sci USA 2001, 98: 7170-7175.
67. Heegaard PM, Pedersen HG, Flink J and Boas U. Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers. FEBS Lett 2004, 577: 127-133.
68. Younan ND, Nadal RC, Davies P, Brown DR and Viles JH. Methionine oxidation perturbs the structural core of the prion protein and suggests a generic misfolding pathway. J Biol Chem 2012, 287: 28263-28275.
69. Wolschner C, Giese A, Kretzschmar HA, Huber R, Moroder L and Budisa N. Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein. Proc Natl Acad Sci USA 2009, 106: 7756-7761.
70. Lisa S, Meli M, Cabello G, Gabizon R, Colombo G and Gasset M. The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines. Cell Mol Life Sci 2010, 67: 2825-2838.
71. Breydo L, Bocharova OV, Makarava N, Salnikov VV, Anderson M and Baskakov IV. Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation. Biochemistry 2005, 44: 15534-15543.
72. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N and Horiuchi S, et al. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993, 92: 1243-1252.
73. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R and Manogue K, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994, 91: 4766-4770.
74. Takeuchi M and Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008, 14: 973-978.
75. Goh SY and Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008, 93: 1143-1152.
76. Chen L, Wei Y, Wang X and He R. D-Ribosylated Tau forms globular aggregates with high cytotoxicity. Cell Mol Life Sci 2009, 66: 2559-2571.
77. Chen L, Wei Y, Wang X and He R. Ribosylation rapidly induces alphasynuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 2010, 5: e9052.
78. Kong FL, Cheng W, Chen J and Liang Y. d-Ribose glycates beta(2)- microglobulin to form aggregates with high cytotoxicity through a ROS-mediated pathway. Chem Biol Interact 2011, 194: 69-78.
79. Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N and Ikeda H, et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 2002, 326: 117-120.
80. Choi YG, Kim JI, Jeon YC, Park SJ, Choi EK, Rubenstein R and Kascsak RJ, et al. Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies. J Biol Chem 2004, 279: 30402-30409.
81. Saborio GP, Permanne B and Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411: 810-813.
82. Castilla J, Saa P, Hetz C and Soto C. In vitro generation of infectious scrapie prions. Cell 2005, 121: 195-206.
83. Wang F, Wang X, Yuan CG and Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010, 327: 1132-1135.
84. Snow AD, Kisilevsky R, Willmer J, Prusiner SB and DeArmond SJ. Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol 1989, 77: 337-342.
85. Snow AD, Wight TN, Nochlin D, Koike Y, Kimata K, DeArmond SJ and Prusiner SB. Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. Lab Invest 1990, 63: 601-611.
86. Aiken JM, Williamson JL, Borchardt LM and Marsh RF. Presence of mitochondrial D-loop DNA in scrapie-infected brain preparations enriched for the prion protein. J Virol 1990, 64: 3265-3268.
87. Kellings K, Meyer N, Mirenda C, Prusiner SB and Riesner D. Further analysis of nucleic acids in purified scrapie prion preparations by improved return refocusing gel electrophoresis. J Gen Virol 1992, 73 (Pt 4): 1025-1029.
88. Klein TR, Kirsch D, Kaufmann R and Riesner D. Prion rods contain small amounts of two host sphingolipids as revealed by thin-layer chromatography and mass spectrometry. Biol Chem 1998, 379: 655-666.
89. Gellermann GP, Appel TR, Tannert A, Radestock A, Hortschansky P, Schroeckh V and Leisner C, et al. Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci USA 2005, 102: 6297-6302.
90. Rudd TR, Skidmore MA, Guerrini M, Hricovini M, Powell AK, Siligardi G and Yates EA. The conformation and structure of GAGs: recent progress and perspectives. Curr Opin Struct Biol 2010, 20: 567-574.
91. Diaz-Nido J, Wandosell F and Avila J. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002, 23: 1323-1332.
92. Shyng SL, Lehmann S, Moulder KL and Harris DA. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem 1995, 270: 30221-30229.
93. Horonchik L, Tzaban S, Ben-Zaken O, Yedidia Y, Rouvinski A, Papy-Garcia D and Barritault D, et al. Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem 2005, 280: 17062-17067.
94. Hijazi N, Kariv-Inbal Z, Gasset M and Gabizon R. PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. J Biol Chem 2005, 280: 17057-17061.
95. Mayer-Sonnenfeld T, Zeigler M, Halimi M, Dayan Y, Herzog C, Lasmezas CI and Gabizon R. The metabolism of glycosaminoglycans is impaired in prion diseases. Neurobiol Dis 2005, 20: 738-743.
96. Gonzalez-Iglesias R, Pajares MA, Ocal C, Espinosa JC, Oesch B and Gasset M. Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. J Mol Biol 2002, 319: 527-540.
97. Pan T, Wong BS, Liu T, Li R, Petersen RB and Sy MS. Cell-surface prion protein interacts with glycosaminoglycans. Biochem J 2002, 368: 81-90.
98. Warner RG, Hundt C, Weiss S and Turnbull JE. Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem 2002, 277: 18421-18430.
99. Yin S, Pham N, Yu S, Li C, Wong P, Chang B and Kang SC, et al. Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans. Proc Natl Acad Sci USA 2007, 104: 7546-7551.
100. Gabizon R, Meiner Z, Halimi M and Ben-Sasson SA. Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol 1993, 157: 319-325.
101. Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly K, Chesebro B and Caughey B. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J 2001, 20: 377-386.
102. Andrievskaia O, Potetinova Z, Balachandran A and Nielsen K. Binding of bovine prion protein to heparin: a fluorescence polarization study. Arch Biochem Biophys 2007, 460: 10-16.
103. Taubner LM, Bienkiewicz EA, Copie V and Caughey B. Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan. J Mol Biol 2010, 395: 475-490.
104. Kellings K, Meyer N, Mirenda C, Prusiner SB and Riesner D. Analysis of nucleic acids in purified scrapie prion preparations. Arch Virol Suppl 1993, 7: 215-225.
105. Kellings K, Prusiner SB and Riesner D. Nucleic acids in prion preparations: unspecific background or essential component? Philos Trans R Soc Lond B Biol Sci 1994, 343: 425-430.
106. Lima LM, Cordeiro Y, Tinoco LW, Marques AF, Oliveira CL, Sampath S and Kodali R, et al. Structural insights into the interaction between prion protein and nucleic acid. Biochemistry 2006, 45: 9180-9187.
107. Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, Foguel D and Silva JL. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 2001, 276: 49400-49409.
108. Nandi PK, Leclerc E, Nicole JC and Takahashi M. DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid. J Mol Biol 2002, 322: 153-161.
109. Grossman A, Zeiler B and Sapirstein V. Prion protein interactions with nucleic acid: possible models for prion disease and prion function. Neurochem Res 2003, 28: 955-963.
110. Cordeiro Y and Silva JL. The hypothesis of the catalytic action of nucleic acid on the conversion of prion protein. Protein Pept Lett 2005, 12: 251-255.
111. Nandi PK. Interaction of prion peptide HuPrP106-126 with nucleic acid. Arch Virol 1997, 142: 2537-2545.
112. Nandi PK. Polymerization of human prion peptide HuPrP 106-126 to amyloid in nucleic acid solution. Arch Virol 1998, 143: 1251-1263.
113. Nandi PK and Leclerc E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch Virol 1999, 144: 1751-1763.
114. Deleault NR, Lucassen RW and Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003, 425: 717-720.
115. Gomes MP, Millen TA, Ferreira PS, e Silva NL, Vieira TC, Almeida MS and Silva JL, et al. Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells. J Biol Chem 2008, 283: 19616-19625.
116. Liu M, Yu S, Yang J, Yin X and Zhao D. RNA and CuCl2 induced conformational changes of the recombinant ovine prion protein. Mol Cell Biochem 2007, 294: 197-203.
117. Vey M, Pilkuhn S, Wille H, Nixon R, DeArmond SJ, Smart EJ and Anderson RG, et al. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci USA 1996, 93: 14945-14949.
118. Taraboulos A, Scott M, Semenov A, Avrahami D, Laszlo L and Prusiner SB. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995, 129: 121-132.
119. Naslavsky N, Shmeeda H, Friedlander G, Yanai A, Futerman AH, Barenholz Y and Taraboulos A. Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J Biol Chem 1999, 274: 20763-20771.
120. Sarnataro D, Campana V, Paladino S, Stornaiuolo M, Nitsch L and Zurzolo C. PrP(C) association with lipid rafts in the early secretory pathway stabilizes its cellular conformation. Mol Biol Cell 2004, 15: 4031-4042.
121. Morillas M, Swietnicki W, Gambetti P and Surewicz WK. Membrane environment alters the conformational structure of the recombinant human prion protein. J Biol Chem 1999, 274: 36859-36865.
122. Boland MP, Hatty CR, Separovic F, Hill AF, Tew DJ, Barnham KJ and Haigh CL, et al. Anionic phospholipid interactions of the prion protein N terminus are minimally perturbing and not driven solely by the octapeptide repeat domain. J Biol Chem 2010, 285: 32282-32292.
123. Critchley P, Kazlauskaite J, Eason R and Pinheiro TJ. Binding of prion proteins to lipid membranes. Biochem Biophys Res Commun 2004, 313: 559-567.
124. Re F, Sesana S, Barbiroli A, Bonomi F, Cazzaniga E, Lonati E and Bulbarelli A, et al. Prion protein structure is affected by pH-dependent interaction with membranes: a study in a model system. FEBS Lett 2008, 582: 215-220.
125. Wang F, Yang F, Hu Y, Wang X, Jin C and Ma J. Lipid interaction converts prion protein to a PrPSc-like proteinase K-resistant conformation under physiological conditions. Biochemistry 2007, 46: 7045-7053.
126. Wang F, Yin S, Wang X, Zha L, Sy MS and Ma J. Role of the highly conserved middle region of prion protein (PrP) in PrP-lipid interaction. Biochemistry 2010, 49: 8169-8176.
127. Sanghera N and Pinheiro TJ. Binding of prion protein to lipid membranes and implications for prion conversion. J Mol Biol 2002, 315: 1241-1256.
128. Luhrs T, Zahn R and Wuthrich K. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. J Mol Biol 2006, 357: 833-841.
129. Dupiereux I, Zorzi W, Lins L, Brasseur R, Colson P, Heinen E and Elmoualij B. Interaction of the 106-126 prion peptide with lipid membranes and potential implication for neurotoxicity. Biochem Biophys Res Commun 2005, 331: 894-901.
130. Miura T, Yoda M, Takaku N, Hirose T and Takeuchi H. Clustered negative charges on the lipid membrane surface induce beta-sheet formation of prion protein fragment 106-126. Biochemistry 2007, 46: 11589-11597.
131. Dorosz J, Volinsky R, Bazar E, Kolusheva S and Jelinek R. Phospholipid-induced fibrillation of a prion amyloidogenic determinant at the air/water interface. Langmuir 2009, 25: 12501-12506.
132. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R and Fraser PE, et al. The cellular prion protein binds copper in vivo. Nature 1997, 390: 684-687.
133. Jackson GS, Murray I, Hosszu LL, Gibbs N, Waltho JP, Clarke AR and Collinge J. Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci USA 2001, 98: 8531-8535.
134. Burns CS, Aronoff-Spencer E, Dunham CM, Lario P, Avdievich NI, Antholine WE and Olmstead MM, et al. Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 2002, 41: 3991-4001.
135. Qin K, Yang Y, Mastrangelo P and Westaway D. Mapping Cu(II) binding sites in prion proteins by diethyl pyrocarbonate modification and matrixassisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric footprinting. J Biol Chem 2002, 277: 1981-1990.
136. Qin K, Yang DS, Yang Y, Chishti MA, Meng LJ, Kretzschmar HA and Yip CM, et al. Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. J Biol Chem 2000, 275: 19121-19131.
137. Quaglio E, Chiesa R and Harris DA. Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform. J Biol Chem 2001, 276: 11432-11438.
138. Wu D, Zhang W, Luo Q, Luo K, Huang L, Wang W and Huang T, et al. Copper (II) promotes the formation of soluble neurotoxic PrP oligomers in acidic environment. J Cell Biochem 2010, 111: 627-633.
139. Bocharova OV, Breydo L, Salnikov VV and Baskakov IV. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 2005, 44: 6776-6787.
140. Orem NR, Geoghegan JC, Deleault NR, Kascsak R and Supattapone S. Copper (II) ions potently inhibit purified PrPres amplification. J Neurochem 2006, 96: 1409-1415.
141. Gustiananda M, Haris PI, Milburn PJ and Gready JE. Copper-induced conformational change in a marsupial prion protein repeat peptide probed using FTIR spectroscopy. FEBS Lett 2002, 512: 38-42.
142. Leclerc E, Serban H, Prusiner SB, Burton DR and Williamson RA. Copper induces conformational changes in the N-terminal part of cellsurface PrPC. Arch Virol 2006, 151: 2103-2109.
143. Wong BS, Chen SG, Colucci M, Xie Z, Pan T, Liu T and Li R, et al. Aberrant metal binding by prion protein in human prion disease. J Neurochem 2001, 78: 1400-1408.
144. Thackray AM, Knight R, Haswell SJ, Bujdoso R and Brown DR. Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem J 2002, 362: 253-258.
145. Hesketh S, Sassoon J, Knight R and Brown DR. Elevated manganese levels in blood and CNS in human prion disease. Mol Cell Neurosci 2008, 37: 590-598.
146. Brown DR, Hafiz F, Glasssmith LL, Wong BS, Jones IM, Clive C and Haswell SJ. Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J 2000, 19: 1180-1186.
147. Brazier MW, Davies P, Player E, Marken F, Viles JH and Brown DR. Manganese binding to the prion protein. J Biol Chem 2008, 283: 12831-12839.
148. Li XL, Dong CF, Wang GR, Zhou RM, Shi Q, Tian C and Gao C, et al. Manganese-induced changes of the biochemical characteristics of the recombinant wild-type and mutant PrPs. Med Microbiol Immunol 2009, 198: 239-245.
149. Levin J, Bertsch U, Kretzschmar H and Giese A. Single particle analysis of manganese-induced prion protein aggregates. Biochem Biophys Res Commun 2005, 329: 1200-1207.
150. Hesketh S, Thompsett AR and Brown DR. Prion protein polymerisation triggered by manganese-generated prion protein seeds. J Neurochem 2012, 120: 177-189.
151. Singh A, Isaac AO, Luo X, Mohan ML, Cohen ML, Chen F and Kong Q, et al. Abnormal brain iron homeostasis in human and animal prion disorders. PLoS Pathog 2009, 5: e1000336.
152. Singh A, Mohan ML, Isaac AO, Luo X, Petrak J, Vyoral D and Singh N. Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis. PLoS One 2009, 4: e4468.
153. Singh N, Das D, Singh A and Mohan ML. Prion protein and metal interaction: physiological and pathological implications. Curr Issues Mol Biol 2010, 12: 99-107.
154. Watt NT and Hooper NM. The prion protein and neuronal zinc homeostasis. Trends Biochem Sci 2003, 28: 406-410.
155. Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I and Perugini M, et al. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 2001, 40: 8073-8084.
156. Colombo G, Meli M, Morra G, Gabizon R and Gasset M. Methionine sulfoxides on prion protein Helix-3 switch on the alpha-fold destabilization required for conversion. PLoS One 2009, 4: e4296.
157. Meli M, Gasset M and Colombo G. Dynamic diagnosis of familial prion diseases supports the beta2-alpha2 loop as a universal interference target. PLoS One 2011, 6: e19093.
158. Bocharova OV, Makarava N, Breydo L, Anderson M, Salnikov VV and Baskakov IV. Annealing prion protein amyloid fibrils at high temperature results in extension of a proteinase K-resistant core. J Biol Chem 2006, 281: 2373-2379.
159. Bazar E, Sheynis T, Dorosz J and Jelinek R. Heparin inhibits membrane interactions and lipid-induced fibrillation of a prion amyloidogenic determinant. Chembiochem 2011, 12: 761-767.
160. Vieira TC, Reynaldo DP, Gomes MP, Almeida MS, Cordeiro Y and Silva JL. Heparin binding by murine recombinant prion protein leads to transient aggregation and formation of RNA-resistant species. J Am Chem Soc 2011, 133: 334-344.
161. Campana V, Zentilin L, Mirabile I, Kranjc A, Casanova P, Giacca M and Prusiner SB, et al. Development of antibody fragments for immunotherapy of prion diseases. Biochem J 2009, 418: 507-515.
162. Horiuchi M, Karino A, Furuoka H, Ishiguro N, Kimura K and Shinagawa M. Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity. Virology 2009, 394: 200-207.
163. Kosmac M, Koren S, Giachin G, Stoilova T, Gennaro R, Legname G and Serbec VC. Epitope mapping of a PrP(Sc)-specific monoclonal antibody: identification of a novel C-terminally truncated prion fragment. Mol Immunol 2011, 48: 746-750.
164. Sekiya S, Noda K, Nishikawa F, Yokoyama T, Kumar PK and Nishikawa S. Characterization and application of a novel RNA aptamer against the mouse prion protein. J Biochem 2006, 139: 383-390.
165. Gomes MP, Vieira TC, Cordeiro Y and Silva JL. The role of RNA in mammalian prion protein conversion. Wiley Interdiscip Rev RNA 2012, 3: 415-428.